Teladoc Health Q1 Earnings Report Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2026
0mins
Should l Buy TDOC?
Source: seekingalpha
- Earnings Performance: Teladoc Health reported a Q1 GAAP EPS of -$0.36, missing expectations by $0.02, indicating pressure on profitability, while revenue of $613.84 million, down 2.5% year-over-year, exceeded market expectations by $3.25 million, reflecting the company's resilience amid market fluctuations.
- 2026 Outlook: The company forecasts full-year 2026 revenue between $2.481 billion and $2.576 billion, slightly below the market consensus of $2.51 billion, with adjusted EBITDA expected to range from $267 million to $306 million, and net loss per share projected between -$1.05 and -$0.75, highlighting uncertainty in future profitability.
- Cash Flow Situation: Teladoc anticipates free cash flow for 2026 to be between $130 million and $170 million, demonstrating some cash generation capability despite challenges, which may support future investments and operations.
- User Growth Expectations: The expected number of U.S. Integrated Care Members is projected to be between 97 million and 100 million, indicating the company's efforts to expand its user base, which, despite a challenging overall market environment, still holds potential for increasing market share.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TDOC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TDOC
Wall Street analysts forecast TDOC stock price to rise
15 Analyst Rating
3 Buy
12 Hold
0 Sell
Hold
Current: 6.960
Low
7.50
Averages
8.91
High
12.00
Current: 6.960
Low
7.50
Averages
8.91
High
12.00
About TDOC
Teladoc Health, Inc. provides virtual healthcare services. Its segments include Teladoc Health Integrated Care (Integrated Care) and BetterHelp. Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed on a B2B basis. BetterHelp segment includes direct-to-consumer mental health platform. The online counseling and therapy services are provided via its network of over 35,000 licensed clinicians leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs. Its Telecare brand is a tech-enabled provider of specialist and allied health care via virtual delivery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Teladoc Health Shares Rise for Seven Consecutive Days
- Stock Price Surge: Teladoc Health's shares rose over 4% on Friday, marking a seven-day winning streak, with a 22% increase since April 30, climbing from $5.95 to approximately $7.30, indicating strong market optimism about its future prospects.
- Strong Monthly Performance: Over the past month, Teladoc's stock has gained 38%, although it is up only 2.7% year-to-date, trailing the S&P 500's approximately 7% gains, reflecting a need for improvement in its relative market performance.
- Business Model Transformation: Analysts highlight that Teladoc is transitioning from a cyclical direct-to-consumer telehealth model to a higher-margin, data-driven business-to-business healthcare platform, which could enhance its long-term profitability and market valuation.
- Improved Financial Health: With improving EBITDA margins, positive free cash flow, and a stronger balance sheet, Teladoc is seen as entering a more scalable profitability phase, supporting potential future valuation re-ratings.
See More
Mixed Earnings Reports from Multiple Companies
- Willis Towers Watson's Weak Performance: The insurer reported only 3% organic revenue growth in Q1, falling short of the 4.8% market expectation, leading to a 12% drop in stock price, despite adjusted earnings exceeding Wall Street forecasts, indicating potential growth challenges ahead.
- Hertz Partners with Uber: Hertz's stock surged about 18% following the announcement of a partnership with Uber, where its new Oro Mobility unit will support Uber's robotaxi initiative, with services expected to launch in the San Francisco Bay area later this year, marking a strategic move into autonomous driving.
- Altria's Earnings Beat Expectations: Altria reported adjusted earnings of $1.32 per share in Q1, surpassing the $1.25 consensus estimate, resulting in a stock increase of over 5%, while reaffirming its full-year adjusted earnings guidance, showcasing stability in the tobacco sector.
- Carrier Global's Strong Results: Carrier Global's Q1 adjusted earnings reached 57 cents, exceeding the expected 51 cents, with revenue of $5.34 billion surpassing the $5.01 billion consensus, leading to an 11% stock increase, reflecting robust performance in the building and refrigeration markets.
See More
FDA Proposes Exclusion of Weight Loss Drug Ingredients
- FDA Proposal: The U.S. Food and Drug Administration (FDA) has proposed to exclude Semaglutide and Tirzepatide from the 503B bulk list, limiting the compounding capabilities of outsourcing facilities, which may impact the market supply and accessibility of these drugs.
- Insufficient Clinical Need: The FDA stated that after reviewing available data, it found no clear clinical need to allow compounding of these drugs from raw ingredients, emphasizing patient safety and medical necessity, which could lead to restrictions on the use of related medications.
- Quality and Safety Concerns: The FDA has expressed concerns regarding the quality and safety of compounded weight-loss drugs, noting that these drugs are not reviewed by the FDA, which may pose risks such as improper storage, dosing errors, and counterfeit products, thereby affecting patient health.
- Market Reaction: Following the FDA proposal, shares of Eli Lilly and Novo Nordisk rose by 9% and 5%, respectively, indicating increased market confidence in the FDA-approved drugs from these companies, while Hims & Hers and Teladoc Health saw slight declines, reflecting market concerns over compounded medications.
See More
Significant Premarket Trading Moves by Multiple Companies
- Meta's CapEx Increase: Meta Platforms raised its full-year capital expenditure guidance to between $125 billion and $145 billion, causing a 9% drop in stock price due to heightened concerns over AI spending, which negatively impacts investor confidence.
- Eli Lilly's Strong Performance: Eli Lilly's first-quarter earnings and revenue exceeded analyst expectations, leading to an almost 8% stock increase, while the company raised its full-year sales outlook to between $82 billion and $85 billion, indicating robust market demand.
- Alphabet's Impressive Earnings: Alphabet reported first-quarter revenue of $109.9 billion, surpassing the $107.2 billion expected by analysts, resulting in a 7.4% stock increase, with Google Cloud revenue soaring 63% year-over-year, showcasing strong growth potential in its cloud business.
- Royal Caribbean's Solid Results: Royal Caribbean's first-quarter adjusted earnings came in at $3.60 per share, exceeding the $3.20 expected by analysts, and despite slightly missing revenue expectations, the stock rose 7%, reflecting market confidence in its financial health.
See More
Stock Futures Slip as Geopolitical Tensions Resurface
- Market Volatility: Stock futures slipped on Thursday morning as geopolitical tensions resurfaced, driving Brent crude to a four-year high, with investors reacting cautiously to reports of potential new military measures against Iran by the Trump administration, indicating market concerns over future uncertainties.
- Qualcomm's Strong Performance: Qualcomm (QCOM) shares surged 13% after reporting FQ2 adjusted EPS of $2.65, exceeding expectations, despite a 3% year-over-year revenue decline to $10.6 billion; growth in automotive (+38%) and IoT (+9%) segments demonstrated the company's resilience in diversifying markets.
- Carvana's Sustained Growth: Carvana (CVNA) shares rose 9% after reporting record revenue and adjusted EBITDA in Q1, with retail units sold climbing 40% to 187,393 and revenue jumping 52% to $6.43 billion, although rising costs led to margin declines, the company anticipates sequential growth in retail units and EBITDA in Q2.
- Alphabet's Strong Results: Alphabet (GOOG) shares advanced 7% after delivering a Q1 revenue increase of 22% year-over-year to $109.9 billion, with net income soaring 81% to $62.6 billion; the cloud segment's 63% revenue growth highlighted ongoing momentum driven by AI, and the company raised its quarterly dividend by 5% to $0.22 per share, reinforcing confidence in cash flow strength.
See More
Teladoc Health Q1 2026 Earnings Call Insights
- Financial Performance Exceeds Expectations: Teladoc reported Q1 2026 revenue of $614 million, surpassing analysts' expectations of $611 million, with adjusted EBITDA of $58 million, demonstrating the company's execution capabilities and market adaptability in integrated care.
- Insurance Market Expansion: The rollout in the U.S. insurance market has exceeded expectations, now live in 30 states and Washington D.C., with over 6,000 credentialed providers and more than 150 million covered lives, which is expected to provide strong support for future revenue growth.
- Optimistic Future Outlook: Teladoc anticipates 2026 consolidated revenue between $2.48 billion and $2.58 billion, with adjusted EBITDA ranging from $267 million to $306 million, reflecting management's confidence in future performance, particularly driven by BetterHelp's insurance business.
- Operational Challenges and Responses: Despite pressures on BetterHelp's direct-to-consumer business, management emphasized addressing these through insurance expansion and disciplined marketing spend, while ensuring adequate therapist capacity to meet demand, highlighting the company's focus on operational capabilities.
See More
Teladoc Health Shares Rise for Seven Consecutive Days
- Stock Price Surge: Teladoc Health's shares rose over 4% on Friday, marking a seven-day winning streak, with a 22% increase since April 30, climbing from $5.95 to approximately $7.30, indicating strong market optimism about its future prospects.
- Strong Monthly Performance: Over the past month, Teladoc's stock has gained 38%, although it is up only 2.7% year-to-date, trailing the S&P 500's approximately 7% gains, reflecting a need for improvement in its relative market performance.
- Business Model Transformation: Analysts highlight that Teladoc is transitioning from a cyclical direct-to-consumer telehealth model to a higher-margin, data-driven business-to-business healthcare platform, which could enhance its long-term profitability and market valuation.
- Improved Financial Health: With improving EBITDA margins, positive free cash flow, and a stronger balance sheet, Teladoc is seen as entering a more scalable profitability phase, supporting potential future valuation re-ratings.
See More
Mixed Earnings Reports from Multiple Companies
- Willis Towers Watson's Weak Performance: The insurer reported only 3% organic revenue growth in Q1, falling short of the 4.8% market expectation, leading to a 12% drop in stock price, despite adjusted earnings exceeding Wall Street forecasts, indicating potential growth challenges ahead.
- Hertz Partners with Uber: Hertz's stock surged about 18% following the announcement of a partnership with Uber, where its new Oro Mobility unit will support Uber's robotaxi initiative, with services expected to launch in the San Francisco Bay area later this year, marking a strategic move into autonomous driving.
- Altria's Earnings Beat Expectations: Altria reported adjusted earnings of $1.32 per share in Q1, surpassing the $1.25 consensus estimate, resulting in a stock increase of over 5%, while reaffirming its full-year adjusted earnings guidance, showcasing stability in the tobacco sector.
- Carrier Global's Strong Results: Carrier Global's Q1 adjusted earnings reached 57 cents, exceeding the expected 51 cents, with revenue of $5.34 billion surpassing the $5.01 billion consensus, leading to an 11% stock increase, reflecting robust performance in the building and refrigeration markets.
See More
FDA Proposes Exclusion of Weight Loss Drug Ingredients
- FDA Proposal: The U.S. Food and Drug Administration (FDA) has proposed to exclude Semaglutide and Tirzepatide from the 503B bulk list, limiting the compounding capabilities of outsourcing facilities, which may impact the market supply and accessibility of these drugs.
- Insufficient Clinical Need: The FDA stated that after reviewing available data, it found no clear clinical need to allow compounding of these drugs from raw ingredients, emphasizing patient safety and medical necessity, which could lead to restrictions on the use of related medications.
- Quality and Safety Concerns: The FDA has expressed concerns regarding the quality and safety of compounded weight-loss drugs, noting that these drugs are not reviewed by the FDA, which may pose risks such as improper storage, dosing errors, and counterfeit products, thereby affecting patient health.
- Market Reaction: Following the FDA proposal, shares of Eli Lilly and Novo Nordisk rose by 9% and 5%, respectively, indicating increased market confidence in the FDA-approved drugs from these companies, while Hims & Hers and Teladoc Health saw slight declines, reflecting market concerns over compounded medications.
See More
Significant Premarket Trading Moves by Multiple Companies
- Meta's CapEx Increase: Meta Platforms raised its full-year capital expenditure guidance to between $125 billion and $145 billion, causing a 9% drop in stock price due to heightened concerns over AI spending, which negatively impacts investor confidence.
- Eli Lilly's Strong Performance: Eli Lilly's first-quarter earnings and revenue exceeded analyst expectations, leading to an almost 8% stock increase, while the company raised its full-year sales outlook to between $82 billion and $85 billion, indicating robust market demand.
- Alphabet's Impressive Earnings: Alphabet reported first-quarter revenue of $109.9 billion, surpassing the $107.2 billion expected by analysts, resulting in a 7.4% stock increase, with Google Cloud revenue soaring 63% year-over-year, showcasing strong growth potential in its cloud business.
- Royal Caribbean's Solid Results: Royal Caribbean's first-quarter adjusted earnings came in at $3.60 per share, exceeding the $3.20 expected by analysts, and despite slightly missing revenue expectations, the stock rose 7%, reflecting market confidence in its financial health.
See More
Stock Futures Slip as Geopolitical Tensions Resurface
- Market Volatility: Stock futures slipped on Thursday morning as geopolitical tensions resurfaced, driving Brent crude to a four-year high, with investors reacting cautiously to reports of potential new military measures against Iran by the Trump administration, indicating market concerns over future uncertainties.
- Qualcomm's Strong Performance: Qualcomm (QCOM) shares surged 13% after reporting FQ2 adjusted EPS of $2.65, exceeding expectations, despite a 3% year-over-year revenue decline to $10.6 billion; growth in automotive (+38%) and IoT (+9%) segments demonstrated the company's resilience in diversifying markets.
- Carvana's Sustained Growth: Carvana (CVNA) shares rose 9% after reporting record revenue and adjusted EBITDA in Q1, with retail units sold climbing 40% to 187,393 and revenue jumping 52% to $6.43 billion, although rising costs led to margin declines, the company anticipates sequential growth in retail units and EBITDA in Q2.
- Alphabet's Strong Results: Alphabet (GOOG) shares advanced 7% after delivering a Q1 revenue increase of 22% year-over-year to $109.9 billion, with net income soaring 81% to $62.6 billion; the cloud segment's 63% revenue growth highlighted ongoing momentum driven by AI, and the company raised its quarterly dividend by 5% to $0.22 per share, reinforcing confidence in cash flow strength.
See More
Teladoc Health Q1 2026 Earnings Call Insights
- Financial Performance Exceeds Expectations: Teladoc reported Q1 2026 revenue of $614 million, surpassing analysts' expectations of $611 million, with adjusted EBITDA of $58 million, demonstrating the company's execution capabilities and market adaptability in integrated care.
- Insurance Market Expansion: The rollout in the U.S. insurance market has exceeded expectations, now live in 30 states and Washington D.C., with over 6,000 credentialed providers and more than 150 million covered lives, which is expected to provide strong support for future revenue growth.
- Optimistic Future Outlook: Teladoc anticipates 2026 consolidated revenue between $2.48 billion and $2.58 billion, with adjusted EBITDA ranging from $267 million to $306 million, reflecting management's confidence in future performance, particularly driven by BetterHelp's insurance business.
- Operational Challenges and Responses: Despite pressures on BetterHelp's direct-to-consumer business, management emphasized addressing these through insurance expansion and disciplined marketing spend, while ensuring adequate therapist capacity to meet demand, highlighting the company's focus on operational capabilities.
See More
